Conflict of interest
Cancer
CANCER
Both Memorial Sloan Kettering Cancer Center (MSK) and Dr. Cheung have financial interest in Y-mAbs, Abpro-Labs and Eureka Therapeutics. Dr. Cheung also reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc. Dr. Cheung was named as inventor on multiple patents filed by MSK, including naxitamab and omburtamab licensed to Ymabs Therapeutics, and others licensed to Biotec Pharmacon, and Abpro-labs. Dr. Cheung is a SAB member for Eureka Therapeutics. Dr. Modak and Dr. Kramer reports consulting and equity in Ymabs, Therapeutics Inc. Omburtamab was licensed to Y-mAbs Therapeutics in 2015. Dr. Karajannis reports grants from Y-mAbs Therapeutics, Inc. (research support) and personal fees from Bayer AG, AstraZeneca, Inc., QED Therapeutics, Inc., CereXis, Inc., Recursion, Inc., Cardinal Health and Medscape (Medical Advisory Board and/or consultant).